ITCI: רווח נקי למניה (EPS TTM) intracellulartherapies.com

Earnings per share over the last four quarters demonstrate how chronic demand for mental disorder therapies stabilizes the cash flows of Intra-Cellular Therapies (ITCI). The value -0.72 captures the magnitude of this parameter. Growth is driven by the expansion of Caplyta through new medical indications, while a strategic alliance with specialized clinics accelerates the commercial scaling of the drug in the US.

Net income per share serves as the key basis for the fundamental valuation of business efficiency. The earnings per share trend over the last four quarters on GURU.Markets reflects the actual return on equity. This metric is calculated as the ratio of total net income to the number of shares, excluding quarterly distortions. For Intra-Cellular Therapies (ITCI), this indicator confirms the monetization of Caplyta's success. Growth in this metric signals scaling sales during the expansion into the MDD segment.